Zinger Key Points
- Haleon reported FY24 revenue of £11.23B ($14.19B), down 0.6%, with 5% organic growth. Adjusted operating profit fell 6.5% to £2.50B.
- 2025 guidance projects 4-6% organic revenue growth, with stronger performance expected in H2. FX headwinds may impact revenue and profit.
- Get 5 stock picks identified before their biggest breakouts, identified by the same system that spotted Insmed, Sprouts, and Uber before their 20%+ gains.
London-based consumer healthcare group Haleon Plc HLN stock is trading lower on Thursday.
Haleon, GSK Plc’s GSK spun off, reported revenue of 11.23 billion pounds (US$14.19 billion) for 2024. That’s down marginally by 0.6%.
Organic revenue growth was 5.0% with +3.7% price and +1.3% volume/mix with +6.8% organic growth in the fourth quarter.
Adjusted operating profit for 2024 stood at 2.5 billion pounds, down 6.5% at constant currency.
- Oral Health: Revenue increased by 5.6% to 3.3 billion, with organic revenue growth of 9.6%.
- Vitamins, Minerals, and Supplements: 2024 revenues increased by 3.4% to 1.7 billion with organic growth of 7.6%, including 8.2% organic growth in Q4 2024.
- Pain Relief: Revenue declined 3.3%, with broadly flat organic growth of 0.1%, resulting in 2.6 billion in revenue.
- Respiratory Health: Revenue declined 3.4% to 1.7 billion, with organic revenue growth of 0.9% and (1.3)% in the fourth quarter.
2024 growth was muted compared to recent years. This reflects a combination of lapping strong cold and flu comparatives arising from significantly elevated Contac demand in China in Q1 2023 from the lifting of COVID-19-related restrictions and a softer cold and flu season in H2 2024, particularly in the US.
Digestive Health and Other revenue declined 7.2% to 2 billion.
Guidance: The company projects 2025 organic revenue to grow between 4% and 6%. Haleon expects organic revenue and operating profit growth to be weighted towards the second half of the year.
The company expects a foreign exchange translation headwind of approximately 1.0% and 2.5% to negatively impact net revenue and adjusted operating profit.
“We are well positioned to drive organic revenue growth within our medium-term guidance range, with strong organic profit growth in 2025,” CEO Brian McNamara said in a statement.
Over the medium term, Haleon expects annual organic revenue growth of 4-6%.
Price Action: HLN stock is down 4.12% at $9.78 during the premarket session at the last check Thursday.
Read Next:
Image: Shutterstock
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.